A genetic modification in the ‘coat’ of a brain infection-causing virus may allow it to escape antibodies, according to Penn State College of Medicine researchers. They say testing people for this and other viral mutations may help identify patients at risk for developing a fatal brain disease.
Dr. Aron Lukacher, professor and chair of the Department of Microbiology and Immunology at the College of Medicine, and Susan Hafenstein, professor of medicine and microbiology and immunology at the College of Medicine and professor of biochemistry and molecular biology at Penn State Eberly College of Science, co-led a research team that used high-resolution microscopy to study the capsid, or outer shell of mouse polyomavirus (MuPyV). This virus is a genetic model of JC polyomavirus (JCPyV), which is present and harmless in most people and can cause progressive multifocal leukoencephalopathy (PML), a brain disease, in people taking immunosuppressive therapies.
Genetic mutations in the capsid of JCPyV are common in PML patients and scientists have struggled to understand whether they allow the virus to infect brain cells or whether the resulting changes allow the virus to evade elimination by antiviral antibodies and then cause brain infection. Lukacher and Hafenstein studied the mouse equivalent of a common genetic mutation in JC polyomavirus to try and better understand how it may cause PML.
“Not much is known about how this particular genetic mutation in the JC polyomavirus capsid leads to PML,” Lukacher said. “It has been detected in the blood, cerebrospinal fluid and brain tissues of PML patients but not in their urine. This unmutated virus typically sits dormant in the kidneys of healthy people, which got us wondering how this particular mutation contributes to disease progression.”
The researchers introduced a genetic mutation in the MuPyV capsid similar to one found in JCPyV and conducted a series of experiments to compare outcomes between MuPyV and the altered virus. The virus mutates by swapping out one amino acid, the chemical ingredients used to build the capsid, for another. They found the virus was still able to cause central nervous system infection and hydrocephalus, or brain swelling.
Top Image Credit: Amanda Scott
Post by Amanda Scott, NA CEO. Follow her on twitter @tantriclens
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen

News
Tricking the novel coronavirus with a fake ‘handshake’
Scientists have developed protein fragments—called peptides—that fit snugly into a groove on the SARS-CoV-2 Spike protein that it would normally use to access a host cell. These peptides effectively trick the virus into "shaking hands" with a replica rather than with [...]
Researchers reveal genetic predisposition to severe COVID-19
HSE University researchers have become the first in the world to discover genetic predisposition to severe COVID-19. The results of the study were published in the journal Frontiers in Immunology. T-cell immunity is one of [...]
What Pseudoviruses Bring to the Study of SARS-CoV-2
When SARS-CoV-2 first began spreading across the globe, not every lab was equipped to study it directly. The virus behind the current pandemic is highly pathogenic and transmissible, leading the US Centers for Disease [...]
Covid-19: Future targets for treatments rapidly identified with new computer simulations
esearchers have detailed a mechanism in the distinctive corona of Covid-19 that could help scientists to rapidly find new treatments for the virus, and quickly test whether existing treatments are likely to work with [...]
Almost Half of Coronavirus Sufferers Report Depression
Almost half of people testing positive for coronavirus have reported symptoms of depression, according to a new study published in the International Journal of Environmental Research and Public Health. Researchers from Bangladesh, the United States [...]
Six previously FDA-approved drugs appear promising against SARS-CoV-2 in laboratory testing
A team of investigators from the Republic of China has discovered that 6 drugs previously approved by the US Food and Drug Administration (FDA) for other indications could be repurposed to treat or prevent [...]
Graphene could one day be used to make quick, reliable tests for viruses like SARS-CoV-2
Graphene is a layer of carbon only one atom thick. Since it was first isolated in 2004, it has found applications in strengthening materials, accelerating electronics, and boosting performance in batteries, among others. It [...]
UK spots 33 cases of ANOTHER Covid variant
Another Covid variant that could dodge vaccine-triggered immunity has been identified in the UK, scientists say. The strain — called B.1.525 — has been spotted 33 times already but experts say this could be [...]
Spotlight on mRNA vaccines: Covid-19 approvals highlight a novel competitive landscape in oncology
The ongoing Covid-19 pandemic has yielded an unexpected advancement in the pharmaceutical industry with the approval of the first mRNA vaccines, which GlobalData expects will soon impact other indications. This historical landmark could have [...]
New AI Tool Can Thwart Coronavirus Mutations
USC researchers have developed a new method to counter emergent mutations of the coronavirus and hasten vaccine development to stop the pathogen responsible for killing thousands of people and ruining the economy. Using artificial [...]
Pfizer vaccine: Single dose ‘90 per cent effective after 21 days’
A single dose of the Pfizer coronavirus vaccine is “highly protective” after three weeks, according to a study. Researchers at the University of East Anglia (UEA) said the coronavirus vaccine developed by Pfizer and BioNTech was still effective [...]
COVID-19 Attack On Brain, Not Lungs, Triggers Severe Disease In Mice
Summary: Mice exposed to COVID-19 through the nasal passage, researchers noted a rapid and escalated attack on the brain by the virus that triggered a more severe outcome of the infection, even after the lungs [...]
GSK and CureVac sign £132m deal to develop multi-variant Covid vaccine
GlaxoSmithKline and Germany’s CureVac have reached a €150m (£132m) agreement to develop a next generation of Covid-19 vaccines targeting new emerging variants in the pandemic. The two companies said they plan to work jointly to [...]
Monoclonal antibodies: ‘great hope’ in Covid treatments fails against variants
The great hope for drug treatments against Covid-19 – the monoclonal antibodies – are failing against variants of the virus, such as those that have emerged in South Africa and Brazil, scientists have found. [...]
Nano ‘Smart bandage’ detects, could prevent infections
Bandages are great for covering wounds, but they would be much more useful if they could also detect infections. By embedding nanosensors in the fibers of a bandage, University of Rhode Island Assistant Professor [...]
Can We Stop a Super Coronavirus?
The new variants of the coronavirus are even more dangerous than those known so far. Researchers and politicians fear a sharp increase in the number of infections, with dramatic consequences like those seen in Britain. [...]